7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens)

Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens)

Hypertension is the leading modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and premature death in Canada, affecting about 1 in 4 adults. Pharmacists screen for it, confirm readings, start or adjust therapy within their scope, and follow patients to target.

---

Measuring Blood Pressure Correctly

The 2025 guideline makes accurate measurement its first recommendation:

• Use a validated automated (oscillometric) device. Automated devices avoid observer error and end-digit rounding. About 90% of devices sold in Canadian pharmacies are validated, compared with less than half of those sold online. Manual auscultation remains preferable when arrhythmia makes automated readings unreliable.
• Use a standardized technique.
  • Have the patient rest quietly for 5 minutes, seated with the back supported, feet flat and legs uncrossed.
  • Bare the arm and support it at heart level, using the correct cuff size with its lower edge about 3 cm above the elbow crease.
  • The patient should not talk during the rest or the readings.
  • Take 3 readings at 1-minute intervals and average them.
  • Non-standardized office readings run about 5 to 10 mmHg higher.
• Confirm out of the office. An elevated office reading should be confirmed with daytime ambulatory monitoring (ABPM) or home monitoring (HBPM).
  • ABPM records every 20 to 30 minutes over day and night.
  • Standard HBPM means duplicate readings morning and evening for one week.
  • When out-of-office monitoring is not feasible, repeat standardized office measurement at a separate visit.

---

Diagnostic Phenotypes: White-Coat and Masked Hypertension

                              DIAGNOSTIC PHENOTYPE MATRIX

                                    OUT-OF-OFFICE BP (daytime ABPM / HBPM)
                                ┌────────────────────────┬────────────────────────┐
                                │   NORMAL (< 130/80)    │  ELEVATED (≥ 130/80)   │
┌───────────────────────────────┼────────────────────────┼────────────────────────┤
│ STANDARDIZED OFFICE BP        │   NORMOTENSION         │  MASKED HYPERTENSION   │
│ NORMAL (< 130/80)             │                        │  Treat as hypertension │
├───────────────────────────────┼────────────────────────┼────────────────────────┤
│ STANDARDIZED OFFICE BP        │ WHITE-COAT HYPERTENSION│ SUSTAINED HYPERTENSION │
│ ELEVATED (≥ 130/80)           │ Monitor yearly         │ Manage per algorithm   │
└───────────────────────────────┴────────────────────────┴────────────────────────┘

• White-coat hypertension (elevated in the office, normal outside): present in about 15% to 30% of people with high office readings. It carries lower risk than sustained hypertension. Do not start drugs on office readings alone; continue yearly monitoring, because many patients progress.
• Masked hypertension (normal in the office, elevated outside): about 10% to 15% prevalence, more common in people with diabetes, CKD, or smoking. Risk is similar to sustained hypertension. Suspect it when home readings or target-organ damage do not fit normal office values.

---

When to Start Drugs, and the Single Target

All adults with hypertension get healthy lifestyle advice: weight loss if BMI is 30 or more, less sodium, more potassium-rich foods (unless CKD or drugs raise potassium), regular aerobic activity, limited alcohol, and smoking cessation.

Start pharmacotherapy when either of these applies:

• the confirmed BP is ≥ 140/90 mmHg; or
• the systolic BP is 130–139 mmHg in a person at high cardiovascular risk.

The guideline defines high risk as any of the following:

• established CVD (coronary disease, heart failure, cerebrovascular disease or peripheral artery disease);
• type 1 or type 2 diabetes;
• CKD (eGFR below 60 mL/min/1.73 m², or albuminuria of 3 mg/mmol or more);
• a 10-year Framingham Risk Score of 20% or more; or
• age 75 years or older.

People with systolic 130–139 who are not at high risk start with lifestyle changes and are reassessed every 6 to 12 months.

Target: systolic BP < 130 mmHg for everyone, if tolerated, using standardized measurement. There is no separate diastolic target and no separate diabetes or CKD target. Large trials and meta-analyses (SPRINT, ESPRIT, BPROAD and others) showed fewer cardiovascular events with intensive control. The absolute risks of hypotension, syncope, falls, electrolyte problems and acute kidney injury were low. Exceptions: goals of care, frailty, fall risk, or orthostatic hypotension can justify a higher, individualized target ("as low as reasonably achievable").

Follow-up: reassess every 1 to 3 months until at target, then every 6 to 12 months.

---

The 2025 Treatment Algorithm

   Confirmed hypertension needing drugs
                 │
   STEP 1  Low-dose 2-drug single-pill combination
           (ACEi or ARB + thiazide/thiazide-like diuretic, or ACEi or ARB + DHP CCB)
           Guideline example: irbesartan/HCTZ 300/25 mg, HALF tablet daily
                 │  not at target
   STEP 2  Full-dose combination (irbesartan/HCTZ 300/25 mg, one tablet daily)
                 │  not at target
   STEP 3  Add long-acting DHP CCB (amlodipine 5 mg → 10 mg daily)
                 │  not at target on 3 drugs at maximally tolerated doses
   STEP 4  Add spironolactone 12.5 mg → 25 mg daily and/or refer to a specialist

• Why combination first: About 70% of adults need more than one class. Low doses of two complementary classes add their BP effects while limiting dose-related adverse effects. Single pills lower systolic BP by about 4 mmHg more than the same drugs as separate pills, through better adherence, and often cost less.
• If an SPC is unavailable or not covered: use two separate pills, preferring a long-acting thiazide-like diuretic (chlorthalidone, indapamide) over a thiazide.
• When to start with one drug: if the patient is at high risk of symptomatic hypotension (for example, frail older adults or those with orthostatic hypotension), starting with a single agent is reasonable.
• Pregnancy: ACE inhibitors and ARBs are avoided or stopped in anyone pregnant or trying to conceive. Counsel all patients of childbearing potential about their teratogenic risk.
• Never combine an ACE inhibitor with an ARB.

First-Line Pharmacotherapy Classes & Regimens

Hypertension Canada considers three complementary classes first-line, with ACE inhibitors and ARBs counted as alternatives within one class. The 2025 algorithm starts most patients on two of them together. The individual agents are:

1. Thiazide / Thiazide-Like Diuretics (specifically long-acting thiazide-like agents);
2. Angiotensin-Converting Enzyme (ACE) Inhibitors;
3. Angiotensin Receptor Blockers (ARBs);
4. Dihydropyridine Calcium Channel Blockers (DCCBs).

---

Deep Dive: First-Line Antihypertensive Classes

1. Thiazide & Thiazide-Like Diuretics

                           THIAZIDE VS. THIAZIDE-LIKE DIURETICS

          HYDROCHLOROTHIAZIDE (HCTZ)                   CHLORTHALIDONE / INDAPAMIDE
    ┌────────────────────────────────────┐       ┌────────────────────────────────────┐
    │ • Elimination Half-life: 6–15 hrs  │       │ • Elimination Half-life: 40–60 hrs │
    │ • Duration of Action: 12–16 hrs    │       │   (Chlorthalidone); 14–24h (Indap) │
    │ • Suboptimal nocturnal BP control  │  vs   │ • True 24-hour hemodynamic control │
    │ • Lacks robust solo mortality trial│       │ • Proven reduction in stroke, CV   │
    │   evidence                         │       │   events & death (ALLHAT, SHEP,    │
    │ • Typical Dose: 12.5–25 mg daily   │       │   HYVET)                           │
    └────────────────────────────────────┘       │ • Chlorthalidone: 12.5–25 mg daily │
                                                 │ • Indapamide: 1.25–2.5 mg daily    │
                                                 └────────────────────────────────────┘

• Mechanism: Inhibit the Na+/Cl- cotransporter in the early distal convoluted tubule of the nephron, increasing urinary excretion of sodium and water. Acute blood pressure reduction results from volume depletion; chronic (long-term) reduction is mediated by decreased peripheral vascular resistance (systemic vasodilation).
• Thiazide vs. Thiazide-Like: The 2020 guideline preferred long-acting thiazide-like diuretics (chlorthalidone 12.5–25 mg daily or indapamide 1.25–2.5 mg daily) over hydrochlorothiazide (HCTZ). In 2025, Hypertension Canada accepted HCTZ within single-pill combinations, because the Diuretic Comparison Project found similar cardiovascular outcomes and more hypokalemia with chlorthalidone. A thiazide-like agent is still preferred when the diuretic is given as a separate pill. Chlorthalidone has a half-life of 40–60 hours (compared to 6–15 hours for HCTZ), providing continuous 24-hour BP control, blunting morning blood pressure surges, and demonstrating hard cardiovascular outcome reductions in landmark trials (ALLHAT, SHEP, HYVET). Indapamide has demonstrated significant stroke and mortality reductions in very elderly patients (HYVET) and post-stroke populations (PROGRESS).
• Adverse Effects & Metabolic Derangements:
  • Hypokalemia & Hypomagnesemia: Dose-dependent; increases arrhythmogenic risk.
  • Hyponatremia: Can be severe, particularly in elderly females.
  • Hyperuricemia: Competes with uric acid for renal tubular secretion; can precipitate acute gout flares.
  • Hyperglycemia & New-Onset Diabetes: Reduces insulin secretion and tissue sensitivity, especially when combined with beta-blockers.
  • Hypercalcemia: Enhances distal renal calcium reabsorption (advantageous in osteoporosis, but requires caution in hyperparathyroidism).
• Renal Efficacy Cutoff: Thiazide diuretics lose efficacy when eGFR falls below 30 mL/min/1.73m²; patients with advanced CKD require loop diuretics (e.g., furosemide) for volume control, although indapamide and chlorthalidone retain some vasodilatory action down to an eGFR of 15–20 mL/min/1.73m².

2. Angiotensin-Converting Enzyme (ACE) Inhibitors

• Agents: Ramipril (2.5–10 mg daily), Perindopril (4–8 mg daily), Enalapril (5–20 mg daily), Lisinopril (10–40 mg daily).
• Mechanism: Competitively inhibit kininase II (ACE), preventing the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor and aldosterone stimulant). Concurrently prevents the degradation of bradykinin and substance P, promoting nitric oxide-mediated vasodilation.
• Key Adverse Effects & Clinical Management:
  • Persistent Dry Cough (5% to 20%): Mediated by bradykinin and substance P accumulation in the pulmonary tree. It is non-productive, irritating, not dose-dependent, and more common in females and individuals of East Asian descent. It does not resolve with cough suppressants or bronchodilators; resolution requires drug cessation (subsides within 1 to 4 weeks). Switching to an ARB resolves the cough.
  • Angioedema (0.1% to 0.7%): Life-threatening, bradykinin-mediated swelling of subcutaneous and submucosal tissues, typically affecting the lips, tongue, uvula, and upper respiratory tract. It can occur hours after the first dose or after years of uneventful therapy. Permanent absolute contraindication to all ACE inhibitors. Epinephrine, corticosteroids, and antihistamines may be ineffective as this is not an IgE-mediated histamine reaction.
  • Hyperkalemia: Due to suppressed aldosterone secretion. Risk is multiplied in CKD, diabetes, and concurrent use of potassium supplements, salt substitutes (potassium chloride), trimethoprim, or potassium-sparing diuretics.
  • Hemodynamic Serum Creatinine Increase: Efferent arteriolar vasodilation reduces intraglomerular capillary hydrostatic pressure. An increase in serum creatinine of up to 30% above baseline within 2 weeks is physiologically expected and acceptable, reflecting preservation of glomerular architecture. If creatinine increases by > 30% or serum potassium exceeds 5.5 mmol/L, investigate bilateral renal artery stenosis or severe volume depletion, and reduce dose or hold.

3. Angiotensin II Receptor Blockers (ARBs)

• Agents: Candesartan (8–32 mg daily), Telmisartan (40–80 mg daily), Valsartan (80–320 mg daily), Losartan (50–100 mg daily).
• Mechanism: Competitively and selectively block the AT1 receptor subtype, blocking the vasoconstrictive, aldosterone-secreting, and hypertrophic actions of angiotensin II, while leaving AT2 receptors unopposed.
• Clinical Pearls: Because ARBs do not inhibit ACE, they do not cause bradykinin accumulation. Dry cough incidence is identical to placebo. Angioedema risk is exceptionally low (< 5% cross-reactivity in patients with prior ACEi angioedema); however, Hypertension Canada advises extreme caution or avoiding ARBs if a patient suffered life-threatening laryngeal ACEi angioedema. Monitoring for creatinine and potassium is identical to ACE inhibitors.

4. Dihydropyridine Calcium Channel Blockers (DCCBs)

• Agents: Amlodipine (2.5–10 mg daily), Felodipine (2.5–10 mg daily), Nifedipine XL (30–60 mg daily).
• Mechanism: Selectively block L-type voltage-gated calcium channels in vascular smooth muscle cells, inhibiting calcium influx and causing potent peripheral arteriolar vasodilation without significant negative chronotropic or inotropic effects on the myocardium.
• Adverse Effects & Management:
  • Peripheral Dependent Edema (DCCB Edema): Dose-dependent pedal/ankle swelling occurring in 5% to 15% of patients. Crucial Clinical Distinction: DCCB edema is caused by precapillary arteriolar vasodilation leading to increased intracapillary hydrostatic pressure and fluid extravasation into interstitial tissue; it is not fluid retention or heart failure. Therefore, loop or thiazide diuretics are ineffective and inappropriate for treating isolated DCCB edema. The pharmacological antidote is adding an ACE inhibitor or ARB, which dilates post-capillary venules, normalizing the transcapillary hydrostatic pressure gradient and resolving the edema.
  • Flushing, Headache, Dizziness: Secondary to acute arterial dilation.
  • Gingival Hyperplasia: Rare, dose- and duration-dependent mucosal overgrowth; requires meticulous oral hygiene or drug discontinuation.

5. Non-Dihydropyridine CCBs (Diltiazem, Verapamil)

• Mechanism: Inhibit L-type calcium channels equally in vascular smooth muscle and cardiac conduction tissue (SA and AV nodes, myocardium).
• Clinical Role: Not recommended as first-line monotherapy for uncomplicated hypertension. Indicated when hypertension co-exists with atrial fibrillation (for ventricular rate control) or chronic stable angina in patients who cannot tolerate beta-blockers.
• Contraindications: Strictly contraindicated in Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤ 40%) due to potent negative inotropic actions causing acute decompensation. Concomitant use with beta-blockers markedly increases the risk of severe bradycardia, sinus arrest, and high-degree AV block.

Combination Therapy & Single-Pill Combinations (SPCs)

Most patients with hypertension require two or more antihypertensive medications to achieve guideline targets. Achieving target blood pressure rapidly is critical to preventing early cardiovascular morbidity.

Initial Combination Therapy Is Now the Default

The 2020 guideline reserved initial combination therapy for patients whose BP was at least 20/10 mmHg above target. The 2025 primary care guideline recommends a low-dose two-drug combination, ideally one pill, as initial treatment for most adults who need drugs, whatever the starting BP. The exception is a patient at high risk of symptomatic hypotension, who may start on one agent.

For example, a 58-year-old with confirmed home BP of 146/88 mmHg and no hypotension risk would start on irbesartan/HCTZ 150/12.5 mg daily (half of a 300/25 mg tablet), not on amlodipine alone.

                           PREFERRED COMBINATION REGIMENS

              ┌────────────────────────────────────────────────────────┐
              │            ACE INHIBITOR or ARB (Foundational)         │
              └───────────────────────────┬────────────────────────────┘
                                          │
                     ┌────────────────────┴────────────────────┐
                     ▼                                         ▼
       DIHYDROPYRIDINE CCB                         THIAZIDE-LIKE DIURETIC
     (e.g., Amlodipine 5 mg)                     (e.g., Indapamide 1.25 mg)
  • Potent complementary vasodilation         • Synergistic volume & resistance drop
  • ACEi/ARB eliminates DCCB pedal edema      • ACEi/ARB counters diuretic hypokalemia
  • Zero metabolic derangement                • Superior stroke reduction (PROGRESS)

Advantages of Single-Pill Combinations (SPCs):

• Enhanced Medication Adherence: Reduces pill burden; simplifies daily administration schedules.
• Counteracting Adverse Effect Mechanisms:
  • Combining an ACEi/ARB with a DCCB dilates both precapillary and postcapillary vascular beds, reducing DCCB-induced pedal edema by up to 70%.
  • Combining an ACEi/ARB with a thiazide diuretic blunts diuretic-induced hypokalemia and hyperuricemia because RAAS blockade retains potassium and promotes uricosuria.
• Faster Time to Target: Significantly higher rates of blood pressure control at 3 and 6 months compared to stepped monotherapy.

The Prohibition on Dual RAAS Blockade

Combining an ACE inhibitor with an ARB, or combining either agent with the direct renin inhibitor aliskiren, is strictly prohibited in Canadian clinical practice.

• The Evidence: Two landmark trials—ONTARGET (telmisartan + ramipril) and ALTITUDE (aliskiren + ACEi/ARB in diabetes)—demonstrated that dual RAAS blockade produced no incremental reduction in stroke, myocardial infarction, or cardiovascular death, but caused statistically significant increases in acute renal failure, severe hyperkalemia, and symptomatic hypotension/syncope.

---

Compelling Clinical Indications for Specific Drug Classes

When co-existing medical conditions are present, specific antihypertensive drug classes are mandated based on clinical trial evidence of survival or organ-protective benefit:

---

Pharmacotherapy in Pregnancy & Lactation

Hypertension in pregnancy is classified into pre-existing chronic hypertension, gestational hypertension (developing after 20 weeks gestation without proteinuria), and preeclampsia (hypertension with proteinuria or maternal organ dysfunction).

                           ANTIHYPERTENSIVES IN PREGNANCY

          CONTRAINDICATED (FETOTOXIC)                     RECOMMENDED FIRST-LINE
    ┌────────────────────────────────────┐       ┌────────────────────────────────────┐
    │ • ACE Inhibitors                   │       │ • Oral Labetalol                   │
    │ • Angiotensin Receptor Blockers    │  vs   │ • Methyldopa                       │
    │ • Direct Renin Inhibitors          │       │ • Long-Acting Oral Nifedipine (XL) │
    │ • Mineralocorticoid Antagonists    │       │                                    │
    │ Fetopathy, renal dysgenesis, skull │       │ Proven maternal and fetal safety   │
    │ hypoplasia, oligohydramnios, death │       │ profiles across clinical trials    │
    └────────────────────────────────────┘       └────────────────────────────────────┘

• Strictly Contraindicated Drug Classes:
  • ACE inhibitors, ARBs, and Direct Renin Inhibitors: Fetotoxic in all trimesters, particularly the second and third. Cause fetal renal dysgenesis, oligohydramnios (resulting in pulmonary hypoplasia and limb contractures), skull ossification defects, intrauterine growth restriction, neonatal anuric renal failure, and fetal death.
  • Mineralocorticoid Receptor Antagonists (Spironolactone): Antiandrogenic; causes feminization of male fetuses.
• First-Line Safe Antihypertensives in Pregnancy:
  1. Oral Labetalol: Combined alpha-1 and non-selective beta-blocker; maintains uteroplacental blood flow; first-line agent of choice in Canada.
  2. Methyldopa: Centrally acting alpha-2 agonist; long-standing historical safety record, though can cause maternal sedation, depression, and elevated hepatic transaminases.
  3. Long-Acting Nifedipine (XL): Dihydropyridine CCB; safe throughout pregnancy.

---

Hypertensive Crises: Hypertensive Urgency vs. Hypertensive Emergency

Severe elevations in blood pressure (typically SBP ≥ 180 mmHg and/or DBP ≥ 110–120 mmHg) require immediate clinical triage based on the presence or absence of acute target organ damage.

                             HYPERTENSIVE CRISIS TRIAGE
                                         │
                  Is there ACUTE, PROGRESSIVE TARGET ORGAN DAMAGE?
                  (Encephalopathy, Aortic Dissection, Acute Pulmonary
                   Edema, ACS, Stroke, Acute Renal Failure, Eclampsia)
                                         │
                     ┌───────────────────┴───────────────────┐
                     ▼                                       ▼
                    YES                                     NO
         HYPERTENSIVE EMERGENCY                  HYPERTENSIVE URGENCY
• Immediate ICU admission               • Outpatient or observation unit
• Titratable IV infusions (labetalol,   • Oral medications (captopril, clonidine,
  nicardipine, nitroglycerin)             amlodipine)
• Controlled, gradual reduction         • Gradual reduction over 24–48 hours
• AVOID precipitous drops (ischemia)    • NEVER use sublingual nifedipine!

1. Hypertensive Urgency

• Definition: Severe blood pressure elevation without acute target organ damage.
• Management: Does not require hospitalization or intravenous antihypertensives. Rapidly dropping blood pressure is dangerous, risking cerebral or myocardial hypoperfusion. Treat with oral antihypertensive agents (e.g., oral amlodipine, captopril, or clonidine) and adjust chronic maintenance regimens. Lower blood pressure gradually over 24 to 48 hours with close outpatient follow-up.
• Danger of Sublingual Nifedipine: Sublingual immediate-release nifedipine bite-and-swallow is strictly contraindicated. It produces unpredictable, precipitous drops in blood pressure, inducing severe reflex tachycardia, cerebral hypoperfusion, ischemic stroke, acute myocardial infarction, and death.

2. Hypertensive Emergency

• Definition: Severe blood pressure elevation accompanied by acute, life-threatening target organ damage:
  • Neurological: Hypertensive encephalopathy, acute ischemic stroke, intracranial hemorrhage;
  • Cardiovascular: Acute aortic dissection, acute coronary syndrome, acute pulmonary edema with left ventricular failure;
  • Renal: Acute hypertensive nephrosclerosis / acute renal failure;
  • Obstetric: Severe preeclampsia or eclampsia.
• Management: Requires immediate admission to an intensive care unit (ICU) and treatment with titratable intravenous infusions (e.g., IV labetalol, nicardipine, nitroglycerin, esmolol, sodium nitroprusside).
• Reduction Kinetics: General rule: reduce mean arterial pressure (MAP) by no more than 20% to 25% within the first hour, then toward 160/100 mmHg over the next 2 to 6 hours, normalizing over 24 to 48 hours. Exceptions: Acute aortic dissection requires immediate, aggressive reduction to SBP < 120 mmHg and heart rate < 60 bpm within 20 minutes (using IV beta-blockers before vasodilators to prevent reflex shear stress). In acute ischemic stroke, blood pressure is managed permissively unless thrombolytic therapy (tPA/TNK) is indicated, where BP must be reduced below 185/110 mmHg prior to infusion.

---

Clinical Decision-Making Scenario: Managing Uncontrolled Hypertension in a Diabetic Patient

A 58-year-old male with a 6-year history of type 2 diabetes mellitus visits the community pharmacy. His current medications are metformin 1,000 mg PO BID and empagliflozin 10 mg PO daily. His laboratory values from last week show: eGFR 74 mL/min/1.73m², serum creatinine 98 µmol/L, serum potassium 4.4 mmol/L, HbA1c 7.3%, and urinary albumin-to-creatinine ratio (ACR) 4.8 mg/mmol (elevated microalbuminuria; normal < 2.0 mg/mmol). He has never been prescribed antihypertensives. Today, standardized automated readings in the pharmacy consultation room average 154/92 mmHg, and his one-week home log averages 148/90 mmHg.

Pharmacist Clinical Assessment & Care Plan:

1. Confirm the Diagnosis and Target: Out-of-office readings confirm hypertension (≥ 130/80 mmHg). Under Hypertension Canada's 2025 guideline the target is systolic < 130 mmHg. Diabetes Canada also uses < 130/80 mmHg for people with diabetes.
2. Decide on Drug Therapy: His BP is ≥ 140/90 mmHg, and diabetes makes him high risk, so drug therapy is indicated. As for most patients needing drugs, the 2025 guideline recommends starting with a low-dose two-drug single-pill combination, whatever the distance from target. He has no features suggesting a high risk of symptomatic hypotension.
3. Select Optimal Regimen Based on Compelling Indications: The patient has persistent microalbuminuria (urinary ACR 4.8 mg/mmol). An ACE inhibitor or ARB is mandatory as first-line therapy to provide intraglomerular hemodynamic protection. To form an initial combination, pair the ACEi with a dihydropyridine CCB (e.g., perindopril 3.5 mg / amlodipine 2.5 mg or ramipril 5 mg + amlodipine 5 mg).
4. Monitoring Schedule: Order follow-up laboratory testing for serum creatinine and potassium in 1 to 2 weeks. An increase in serum creatinine of up to 30% is acceptable. Schedule follow-up blood pressure measurement in 2 to 4 weeks.